本文選題：卵巢癌 + E-cadherin�。� 參考：《石河子大學(xué)》2014年碩士論文

【摘要】：目的：通過檢測E-cadherin在晚期卵巢癌原發(fā)灶以及相應(yīng)轉(zhuǎn)移灶中的表達(dá),分析E-cadherin在晚期卵巢癌侵襲、轉(zhuǎn)移中的作用機(jī)制及臨床意義，探討卵巢癌患者的臨床病理特征（年齡、組織分化、臨床分期）對E-cadherin在卵巢癌中陽性表達(dá)率的影響，為以后研究E-cadherin在卵巢癌中的作用機(jī)制提供初步理論依據(jù)。 方法：選取2007年6月至2013年6月就診于石河子大學(xué)第一附屬醫(yī)院，，臨床病理資料完整并經(jīng)手術(shù)切除、病理醫(yī)師證實為原發(fā)卵巢癌的標(biāo)本，收集30例晚期卵巢癌患者的標(biāo)本及相應(yīng)轉(zhuǎn)移灶標(biāo)本30例、卵巢良性腫瘤標(biāo)本28例（均由病理證實）。將這些晚期卵巢癌的原發(fā)灶以及相應(yīng)轉(zhuǎn)移灶、卵巢良性腫瘤組織制成組織芯片，應(yīng)用免疫組織化學(xué)技術(shù)檢測E-cadherin的表達(dá)情況。用SPSS17．0統(tǒng)計軟件分析上述蛋白表達(dá)與卵巢癌患者部分臨床病理參數(shù)關(guān)系。 結(jié)果：1.E-cadherin免疫組化染色定位于胞膜和（或）胞質(zhì)，E-cadherin在卵巢癌原發(fā)灶組、轉(zhuǎn)移灶組、良性腫瘤組的陽性表達(dá)率分別為46.6%(14/30)、20%(6/30)、82.1%(23/28)，其中原發(fā)灶及相應(yīng)轉(zhuǎn)移灶組的陽性表達(dá)率均低于良性腫瘤組，差異具有顯著性(χ2=22.5P＜0.001)；2.E-cadherin在卵巢癌轉(zhuǎn)移灶組的陽性表達(dá)率低于原發(fā)灶組，兩組的表達(dá)差異具有統(tǒng)計學(xué)意義(P＜0.05)。3.E-cadherin的表達(dá)在晚期上皮性卵巢癌原發(fā)灶中不同年齡段以及臨床分期經(jīng)統(tǒng)計學(xué)分析結(jié)果均為P＞0.05，無統(tǒng)計學(xué)意義；E-cadherin的表達(dá)水平在不同病理分級的卵巢癌中有顯著性差異（P＜0.05），在高分化卵巢癌中E-cadherin表達(dá)的平均水平高于中、低分化的腫瘤。 結(jié)論：E-cadherin的低表達(dá)可能與卵巢癌的侵襲轉(zhuǎn)移密切相關(guān)，E-cadherin表達(dá)降低可作為評估卵巢癌浸潤轉(zhuǎn)移能力的指標(biāo)。
[Abstract]:Objective: to investigate the expression of E-cadherin in the primary and metastatic tumors of advanced ovarian cancer, to analyze the mechanism and clinical significance of E-cadherin in the invasion and metastasis of advanced ovarian cancer, and to explore the clinicopathological features of patients with advanced ovarian cancer. The effect of tissue differentiation and clinical stage on the positive expression of E-cadherin in ovarian cancer provides a theoretical basis for the further study of the mechanism of E-cadherin in ovarian cancer. Methods: selected from June 2007 to June 2013 at the first affiliated Hospital of Shihezi University, the clinicopathological data were complete and surgically resected, pathologists confirmed the specimens of primary ovarian cancer. 30 cases of advanced ovarian cancer and 30 cases of metastasis were collected, and 28 cases of benign ovarian tumors were collected (all confirmed by pathology). Tissue microarray was made from the primary tumor and the corresponding metastasis of these advanced ovarian cancer tissues, and the expression of E-cadherin was detected by immunohistochemical technique. SPSS 17.0 statistical software was used to analyze the relationship between the above protein expression and some clinicopathological parameters of ovarian cancer patients. Results 1. The immunohistochemical staining of E-cadherin was located in the primary tumor group of ovarian cancer and the metastatic tumor group, and was located in the cell membrane and / or cytoplasm of E-cadherin. The positive rate of positive expression in benign tumor group was 46.6% (14 / 30) or 20% (6 / 30) or 82.1% (23 / 28) respectively. The positive rate of positive expression in primary tumor group and corresponding metastatic tumor group was lower than that in benign tumor group (蠂 ~ 2 + 22.5 P < 0.001) 2.The positive rate of E-cadherin in ovarian cancer metastasis group was lower than that in primary tumor group. The expression of E-cadherin was significantly different between the two groups (P < 0.05). 3. The expression of E-cadherin in the primary lesions of advanced epithelial ovarian cancer was statistically significant (P > 0.05), and there was no significant difference in the expression of E-cadherin in different age groups and clinical stages of advanced epithelial ovarian cancer (P > 0.05). The expression level of E-cadherin was significantly different in ovarian cancer with different pathological grade (P < 0.05), and the average expression level of E-cadherin in well-differentiated ovarian carcinoma was higher than that in moderately and poorly differentiated ovarian carcinoma (P < 0.05). Conclusion the low expression of E-cadherin may be closely related to the invasion and metastasis of ovarian cancer. The decreased expression of E-cadherin may be used as an index to evaluate the ability of invasion and metastasis of ovarian cancer.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 高志光,秦環(huán)龍;腸上皮細(xì)胞緊密連接的生物學(xué)功能及在腸屏障中的作用[J];腸外與腸內(nèi)營養(yǎng);2005年05期

2 于月成;辛?xí)匝?李紅梅;楊勇;李奇靈;張明;王曉紅;;E-鈣黏附素及β-連環(huán)蛋白在上皮性卵巢癌中的表達(dá)及臨床意義[J];第四軍醫(yī)大學(xué)學(xué)報;2006年10期

3 蔣靜;謝宛玉;曹建國;;中晚期卵巢癌的治療現(xiàn)狀[J];腫瘤藥學(xué);2013年06期

4 趙陽;許峰;任宏;張云鋒;李曉軍;;E-cadherin基因啟動子C-160A SNP與胃癌的相關(guān)性[J];西安交通大學(xué)學(xué)報(醫(yī)學(xué)版);2013年02期

本文編號：2058448